71 assets in Fallopian Tube Carcinoma

Therapeutic assets addressing Fallopian Tube Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Talazoparib Fallopian Tube Carcinoma	M.D. Anderson Cancer Center	P1	CCC (49)
Autologous Natural Killer Cell-Like Ctls Fallopian Tube Carcinoma	Roswell Park Cancer Institute	P1/2	CCC (48)
Tilt-123 Fallopian Tube Carcinoma	TILT Biotherapeutics Ltd.	P1/2	CC (47)
Tolinapant Fallopian Tube Carcinoma	National Cancer Institute (NCI)	P1/2	CC (47)
Mirvetuximab Fallopian Tube Carcinoma	Shattuck Labs, Inc.	P1	CC (46)
sl-172154 Fallopian Tube Carcinoma	Shattuck Labs, Inc.	P1	CC (46)
Dordaviprone Fallopian Tube Carcinoma	Ira Winer	P2	CC (45)
Autologous Muc1-Activated T-Cells Fallopian Tube Carcinoma	Mayo Clinic	P1	CC (43)
Bendamustine Fallopian Tube Carcinoma	Mayo Clinic	P1	CC (43)
Cobimetinib Fallopian Tube Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Dostarlimab Fallopian Tube Carcinoma	University of Washington	P1	CC (43)
Elimusertib Fallopian Tube Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Pelcitoclax Fallopian Tube Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Prgn-3005 Ultracar-T Cells Fallopian Tube Carcinoma	Precigen, Inc	P1	CC (43)
Capivasertib Fallopian Tube Carcinoma	M.D. Anderson Cancer Center	P1	CC (41)
Genetically Engineered Ny-Eso-1-Specific T Lymphocytes Fallopian Tube Carcinoma	Roswell Park Cancer Institute	P1	CC (41)
Sapanisertib Fallopian Tube Carcinoma	National Cancer Institute (NCI)	P1	CC (41)
Vistusertib Fallopian Tube Carcinoma	M.D. Anderson Cancer Center	P1	CC (41)
Azenosertib Fallopian Tube Carcinoma	OHSU Knight Cancer Institute	Early P1	C (39)
Alpha-Type-1 Polarized Dendritic Cells Fallopian Tube Carcinoma	Roswell Park Cancer Institute	P1/2	C (34)
rp12146 Fallopian Tube Carcinoma	Rhizen Pharmaceuticals SA	P1	NR ()

Showing 51 to 71 of 71 assets

PreviousPage 2 of 2Next